The €446k Business Case for Medtech Electronic Submissions
Due to increased regulatory requirements, the pre-submission phase now consumes at least 50% of assessment time – forcing Medtech manufacturers to delay or abandon EU market entry entirely. The result? A 40% decline in EU-first launches.
To reverse this trend, experts from ABHI, AKRA TEAM, Axon Lawyers, and Scarlet outline how electronic submissions enable faster reviews and a predictable regulatory environment, delivering:
- Significant ROI where modest 10% efficiency gains translate into €446k in savings per cycle
- Faster market access by digitizing and optimizing the pre-submission phase
- Seamless EU-UK data flow by removing repetitive regulatory hurdles
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper